On Wednesday, Pfizer Inc. (NYSE:PFE) said the company is voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.
Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
Pfizer’s decision is based on the totality of clinical data indicating that the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population.
Also Read: FDA Battles Backlog of Drug Factory Inspections Since COVID-19.
The data suggest an imbalance in vaso-occlusive crises and fatal events that require further assessment.
A vaso-occlusive ...
